<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepat Mon</journal-id><journal-id journal-id-type="iso-abbrev">Hepat Mon</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>Hepatitis Monthly</journal-title></journal-title-group><issn pub-type="ppub">1735-143X</issn><issn pub-type="epub">1735-3408</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22783347</article-id><article-id pub-id-type="pmc">3389361</article-id><article-id pub-id-type="doi">10.5812/hepatmon.6438</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Randomized Controlled Trial of Two Schedules of Hepatitis B Vaccination in Predialysed Chronic Renal Failure Patients</article-title><alt-title alt-title-type="short">Hepatitis B Vaccination and Renal Failure</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahmadi</surname><given-names>Farokhlagha</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramezani</surname><given-names>Morteza</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Razeghi</surname><given-names>Effat</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ranjbarnovin</surname><given-names>Neda</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Khazaeipour</surname><given-names>Zahra</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="COR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Nephrology Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IR Iran</aff><aff id="A2"><label>2</label>Department of Nephrology, Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran</aff><aff id="A3"><label>3</label>Brain and Spinal Injury Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IR Iran</aff><author-notes><corresp id="COR1"><label>*</label>Corresponding author: Zahra Khazaeipour, Nephrology Research Center, Brain and Spinal Cord Injury Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IR Iran. Tel.: +98-66581561, Fax: +98-216693885, E-mail: <email>z_kh14@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>30</day><month>5</month><year>2012</year></pub-date><volume>12</volume><issue>5</issue><fpage>344</fpage><lpage>348</lpage><history><date date-type="received"><day>23</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>28</day><month>3</month><year>2012</year></date><date date-type="rev-recd"><day>29</day><month>2</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012, Kowsar Corp.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract abstract-type="executive-summary"><sec id="st1"><title>Background</title><p>Patients with chronic renal disease should be vaccinated as soon as dialysis is forestalled, and this could improve the seroconversion of hepatitis B vaccination.</p></sec><sec id="st2"><title>Objectives</title><p>In this study, we aimed to compare seroconversion and immune response rates using 4 doses of 40 &#x003bc;g and 3 doses of 20 &#x003bc;g Euvax B recombinant Hepatitis B surface Antigen (HBs Ag) vaccine administered to predialysis patients with chronic kidney disease (CKD).</p></sec><sec id="st3"><title>Patients and Methods</title><p>In an open, randomized clinical trial, we compared seroconversion rates in 51 predialysis patients with mild and moderate chronic renal failure who received either 4 doses of 40 &#x003bc;g or 3 doses of 20 &#x003bc;g of Euvax B recombinant hepatitis B vaccine administered at 0, 1, 2, 6 and 0, 1, 6 months, respectively.</p></sec><sec id="st4"><title>Results</title><p>Differences in seroconversion rates after 4 doses of 40 &#x003bc;g (80.88%) compared to 3 doses of 20 &#x003bc;g (92%) were not significant (P = 0.4124). The mean HBs antibody level after 4 doses of 40 &#x003bc;g at 0, 1, 2, and 6 months (182.2 &#x000b1; 286.7) was significantly higher than that after 3 doses of 40 &#x003bc;g at 0,1, and 6 months (96.9 &#x000b1; 192.1) (P = 0.004). Seroconversion after 4 doses of 40 &#x003bc;g (80.8%) was also significantly higher than that after 3 doses of 40 &#x003bc;g (77%) (P = 0.004). Multivariable analysis showed that none of the variables contributed to seroconversion.</p></sec><sec id="st5"><title>Conclusions</title><p>We found that 4 doses of 40 &#x003bc;g did not lead to significantly more seroconversion than 3 doses of 20 &#x003bc;g.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Kidney Failure, Chronic</kwd><kwd>Hepatitis B</kwd><kwd>Vaccination</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Background</title><p>Chronic kidney disease (CKD) and its treatment enhance the risk of Hepatitis B Virus (HBV) infection [<xref ref-type="bibr" rid="R1">1</xref>]. Since 1982, the HBV vaccine has been recommended for CKD patients and healthcare workers [<xref ref-type="bibr" rid="R2">2</xref>][<xref ref-type="bibr" rid="R3">3</xref>][<xref ref-type="bibr" rid="R4">4</xref>][<xref ref-type="bibr" rid="R5">5</xref>]. Patients with CKD are immunocompromised, whether they are on dialysis or not, and have lower immune response rates (50&#x02013;80%) to the vaccine when compared with immunocompetent individuals (95%) [<xref ref-type="bibr" rid="R6">6</xref>][<xref ref-type="bibr" rid="R7">7</xref>][<xref ref-type="bibr" rid="R8">8</xref>]. Different strategies have been employed to improve the immune response in CKD patients, such as increasing the number of intramuscular (i.m.) doses [<xref ref-type="bibr" rid="R9">9</xref>], increasing the quantity of antigen in each dose [<xref ref-type="bibr" rid="R10">10</xref>], intradermal administration [<xref ref-type="bibr" rid="R11">11</xref>], and co-administration of immunogenic or immunostimulant agents such as zinc [<xref ref-type="bibr" rid="R12">12</xref>], levamizole [<xref ref-type="bibr" rid="R13">13</xref>], gammainterferon [<xref ref-type="bibr" rid="R14">14</xref>] interleukin-2 [<xref ref-type="bibr" rid="R15">15</xref>], granulocyte colony stimulating factor, and erythropoietin [<xref ref-type="bibr" rid="R16">16</xref>]. To improve vaccination response, it is advised that CKD patients should be vaccinated as early in the course of renal disease as possible [<xref ref-type="bibr" rid="R17">17</xref>] using a double vaccine dose [<xref ref-type="bibr" rid="R17">17</xref>][<xref ref-type="bibr" rid="R18">18</xref>] and a 4- rather than 3-dose schedule [<xref ref-type="bibr" rid="R6">6</xref>]. Several studies in predialysis patients that have compared vaccine responses to the different doses have been inconclusive [<xref ref-type="bibr" rid="R19">19</xref>][<xref ref-type="bibr" rid="R20">20</xref>][<xref ref-type="bibr" rid="R21">21</xref>]. The current vaccination strategy for predialysis patients at our centers (Imam Khomeini hospital complex and Sina hospital) is 20 &#x003bc;g (1 ml) administered at 0, 1, and 6 months. We aimed to test a new vaccination schedule because we thought the current method ineffective. In this study, we aimed to compare seroconversion rates (Hepatitis B surface Antibody [HBs Ab] &#x02265; 10 mIU/ml) using 4 doses of 40 &#x003bc;g and 3 doses of 20 &#x003bc;g of Euvax B recombinant Hepatitis B surface Antigen (HBs Ag) vaccine administered to predialysis CKD patients.</p></sec><sec id="s2"><title>2. Patients and Methods</title><sec id="s2sub6"><title>2.1. Sample Size</title><p>In accordance with the McNulty et al. study [<xref ref-type="bibr" rid="R22">22</xref>], to perform an analysis with 80% power using a two-sided alpha level (&#x003b1; = 0.05) and assuming 66% and 81% seroconversion with the 20 &#x003bc;g and 40 &#x003bc;g hepatitis B vaccine, we needed to enroll 137 patients. All the available patients who met the inclusion criteria were recruited for this study.</p></sec><sec id="s2sub7"><title>2.2. Patients</title><p>The patients were recruited for the study from the renal outpatient clinics (Imam Khomeini hospital complex and Sina hospital) at Tehran University of Medical Sciences, which provide diagnostic and follow-up services for patients with renal disease, between October 2008 and October 2009. Inclusion criteria were age &#x0003e; 18 years, mild or moderate chronic renal failure (a serum creatinine level = 1.5&#x02013;6 mg/dl). Exclusion criteria were severe renal failure (a serum creatinine level &#x0003e; 6 mg/dl) requiring dialysis or expected to require dialysis within 1 year, patients with positive HBs Ag, HBs Ab, or HBc Ab, patients receiving immunosuppressive treatment, and those with known lymphoproliferative disorder.</p></sec><sec id="s2sub8"><title>2.3. Trial Protocol</title><p>Records were made of demographic details, drug therapy, and the weight and height of the patients. Baseline blood samples were taken to determine the full blood count and blood chemistry, including Fasting Blood Sugar (FBS), C Reactive Protein (CRP), intact Parathyroid Hormone (iPTH), lipid profile, Albumin (Alb), Creatinin (Cr), Ferritin, and hepatitis B and C markers. Randomization process: A 4-block randomized method was used. Patients were randomized to receive 3 doses of 20 &#x003bc;g (1 ml) or 4 doses of 40 &#x003bc;g (2 ml) of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminum hydroxide adjuvant; LG Life Sciences). All cases were followed until the vaccination processes were completed, and there were no withdrawals. Blinding: Blinding was not possible, because the frequency of vaccination in the two groups was unequal. The vaccine was administered (i.m.) into the deltoid muscle using a 23G &#x000d7; 1&#x0201d; needle at 0, 1, and 6 months (3-dose group) and at 0, 1, 2, and 6 months (4-dose group). Patients were followed to assess routine laboratory markers of chronic kidney disease (Glomerular filtration rate [GFR], Cr, Na, K, Ca, P, and so on) and a clinical examination was performed every 3 months. GFR was calculated using the Cockcroft-Gault formula, where GFR ml/min = (140-age) &#x000d7; weight &#x000d7; K / Cr &#x000d7; 72 and K = 1 (for males) or 0.85 (for females). Blood samples were taken before 6 months as well as 8&#x02013;10 weeks after the 6-month dose, and were assayed for the presence of antibodies against HBs Ag (anti-HBs) using a commercial enzyme immunoassay (EIA) produced by Abbott Laboratories (AUSAB, Abbott Laboratories, Abbott Park, IL, USA).</p></sec><sec id="s2sub9"><title>2.4. Hepatitis B Markers</title><p>Hepatitis B surface antibody was determined using an anti-hepatitis B surface antibody quantitative chemiluminescence assay (EIA) produced by Abbott Laboratories (AUSAB, Abbott Laboratories, Abbott Park, IL, USA) at Noor laboratory, Tehran, Iran. Anti-HBs titers are expressed in mIU/ml compared with standard immunoglobulin preparations (Ortho- Clinical Diagnostics). Anti-HBs titers &#x0003c; 10 mIU/ml were defined as non-seroconversion (non-responder). Anti-HBs titers &#x02265; 10 mIU/ml were defined as seroconversion.</p></sec><sec id="s2sub10"><title>2.5. Data Analysis</title><p>After evaluating the normality of the data using a One-Sample Kolmogorov-Smirnov Test, quantitative variables for the 2 qualitative groups were analyzed using a Mann-Whitney U test. The Wilcoxon Signed Ranks test was used for before and after comparisons of quantitative data. Associations between qualitative data were tested using a Chi-square test. Correlations between 2 quantitative variables were evaluated by Spearman&#x02019;s correlation analysis. Logistic regression analysis model was used to evaluate predictors of response to vaccination. In this model , responses to 3 doses of 20 &#x003bc;g and 4 doses of 40 &#x003bc;g of HBs Ab (&#x0003c; 10 and &#x02265; 10 mIU/ml) were dependent variables and type of vaccination, age, ferritin, FBS, HDL, Alb, weight, and HCV Ab were independent variables. Quantitative variables were presented as mean &#x000b1; standard deviation (SD). The significance level was set at P &#x02264; 0.005. Ethics: Since 1996, the English National Immunization Guide [<xref ref-type="bibr" rid="R8">8</xref>] has recommended that &#x0201c;in addition to those already on hemodialysis, the immunization of all patients with chronic renal failure is recommended, as soon as it is anticipated they may require dialysis&#x0201d;. An information sheet explaining the randomization process, the vaccination dose, follow-up, and the rationale for the study was provided to the patients. We obtained their written consent to participate in the study after they had read the information leaflet and discussed it with us. The study was approved by the research ethics committee of Tehran University of Medical Sciences.</p></sec></sec><sec id="s3"><title>3. Results</title><p>Of 64 predialysis patients, 51 completed the 8-month follow-up (26 patients received 4 doses of 40 &#x003bc;g, and 25 patients 3 doses of 20 &#x003bc;g). Two of the remaining patients died, 2 required dialysis, and 9 were eliminated from the study because of problems reaching Tehran from other cities. There were no significant differences in the frequency and etiology of withdrawal between the 2 groups. The patients all had stage 3 or 4 renal failure, but gender differed significantly between the 2 groups: 8 patients (32.0%) in the 3-dose group and 18 (69.2%) in the 4-dose group were male (P = 0.008). Analysis of the age, weight, serum Cr, Alb, Hb, CRP, PTH, ferritin, FBS, LDL, HDL, cholesterol, and GFR of the 51 patients at enrolment did not reveal any significant differences between the 2 study groups (<xref ref-type="table" rid="s3tbl1">Table 1</xref>). The etiology of renal disease was as follows: glomerulonephritis 9.8%, diabetes mellitus 13.7%, polycystic kidney disease 11.7%, hypertension 35.3%, diabetes mellitus and hypertension 9.8%, benign prostatic hypertrophy 9.9%, and unknown etiology 9.8%. There were no significant differences in the etiology of renal disease between the 2 groups. Three patients in the 3-dose group (12%) and 4 in the 4-dose group (15.4%) had diabetes mellitus (P = 0.52). In addition, 3 patients in the 3-dose group were HCV Ab positive.</p><table-wrap id="s3tbl1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Description of Demographic and Clinicopathologic Characteristics of Study Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><bold>20 &#x000b5;g - 3 Dose Group (n = 25)</bold></td><td rowspan="1" colspan="1"><bold>40 &#x000b5;g - 4 Dose Group (n = 26)</bold></td><td rowspan="1" colspan="1"><italic><bold>P</bold></italic><bold> value </bold><xref ref-type="table-fn" rid="Fs3tbl1b">b</xref></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Gender, No.</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.008 <xref ref-type="table-fn" rid="Fs3tbl1c">c</xref></td></tr><tr><td style="padding-left:25pt;" rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:25pt;" rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Weight, kg, mean &#x000b1; SD</td><td rowspan="1" colspan="1">72.6 &#x000b1; 9.3</td><td rowspan="1" colspan="1">69.7 &#x000b1; 6.6</td><td rowspan="1" colspan="1">0.12</td></tr><tr><td rowspan="1" colspan="1">Age, y, mean &#x000b1; SD</td><td rowspan="1" colspan="1">56.9 &#x000b1; 13.0</td><td rowspan="1" colspan="1">57.1 &#x000b1; 11.9</td><td rowspan="1" colspan="1">0.76</td></tr><tr><td rowspan="1" colspan="1">GFR <xref ref-type="table-fn" rid="Fs3tbl1a">a</xref>, ml/min, mean &#x000b1; SD</td><td rowspan="1" colspan="1">31.8 &#x000b1; 10.9</td><td rowspan="1" colspan="1">34.9 &#x000b1; 13.9</td><td rowspan="1" colspan="1">0.46</td></tr><tr><td rowspan="1" colspan="1">Albumin, g/dl, mean &#x000b1; SD</td><td rowspan="1" colspan="1">4.6 &#x000b1; 0.4</td><td rowspan="1" colspan="1">4.4 &#x000b1; 0.4</td><td rowspan="1" colspan="1">0.10</td></tr><tr><td rowspan="1" colspan="1">Creatinine, mg/dl, mean &#x000b1; SD</td><td rowspan="1" colspan="1">2.7 &#x000b1; 1.0</td><td rowspan="1" colspan="1">2.6 &#x000b1; 0.8</td><td rowspan="1" colspan="1">0.95</td></tr><tr><td rowspan="1" colspan="1">Hb <xref ref-type="table-fn" rid="Fs3tbl1a">a</xref>, g/dl, mean &#x000b1; SD</td><td rowspan="1" colspan="1">11.6 &#x000b1; 2.0</td><td rowspan="1" colspan="1">12.3 &#x000b1; 1.9</td><td rowspan="1" colspan="1">0.52</td></tr><tr><td rowspan="1" colspan="1">CRP <xref ref-type="table-fn" rid="Fs3tbl1a">a</xref>, mg/dl, mean &#x000b1; SD</td><td rowspan="1" colspan="1">2.9 &#x000b1; 4.4</td><td rowspan="1" colspan="1">3.4 &#x000b1; 4.5</td><td rowspan="1" colspan="1">0.84</td></tr><tr><td rowspan="1" colspan="1">PTH <xref ref-type="table-fn" rid="Fs3tbl1a">a</xref>, pmol/l, mean &#x000b1; SD</td><td rowspan="1" colspan="1">153.2 &#x000b1; 149.0</td><td rowspan="1" colspan="1">103.9 &#x000b1; 78.2</td><td rowspan="1" colspan="1">0.27</td></tr><tr><td rowspan="1" colspan="1">Ferritin, ng/ml, mean &#x000b1; SD</td><td rowspan="1" colspan="1">120.0 &#x000b1; 94.6</td><td rowspan="1" colspan="1">132.8 &#x000b1; 113.6</td><td rowspan="1" colspan="1">0.77</td></tr><tr><td rowspan="1" colspan="1">FBS <xref ref-type="table-fn" rid="Fs3tbl1a">a</xref>, mg/dl, mean &#x000b1; SD</td><td rowspan="1" colspan="1">105.9 &#x000b1; 34.2</td><td rowspan="1" colspan="1">111.2 &#x000b1; 34.9</td><td rowspan="1" colspan="1">0.22</td></tr><tr><td rowspan="1" colspan="1">LDL <xref ref-type="table-fn" rid="Fs3tbl1a">a</xref>, mg/dl, mean &#x000b1; SD</td><td rowspan="1" colspan="1">100.8 &#x000b1; 30.9</td><td rowspan="1" colspan="1">87.4 &#x000b1; 24.9</td><td rowspan="1" colspan="1">0.10</td></tr><tr><td rowspan="1" colspan="1">HDL <xref ref-type="table-fn" rid="Fs3tbl1a">a</xref>, mg/dl, mean &#x000b1; SD</td><td rowspan="1" colspan="1">42.0 &#x000b1; 12.8</td><td rowspan="1" colspan="1">44.9 &#x000b1; 16.3</td><td rowspan="1" colspan="1">0.59</td></tr><tr><td rowspan="1" colspan="1">Cholesterol, mg/dl, mean &#x000b1; SD</td><td rowspan="1" colspan="1">185.7 &#x000b1; 44.2</td><td rowspan="1" colspan="1">170.8 &#x000b1; 39.6</td><td rowspan="1" colspan="1">0.19</td></tr></tbody></table><table-wrap-foot><fn id="Fs3tbl1a"><p><sup>a</sup> Abbreviations: CRP, C Reactive Protein; FBS, Fasting Blood Sugar; GFR, Glomerular filtration rate Hb, Hepatitis B; HDL, High-density lipoprotein; LDL, Low-density lipoproteinm, PTH, Parathyroid Hormone; GFR, Glomerular filtration rate</p></fn><fn id="Fs3tbl1b"><p><sup>b</sup> Mann-Whitney U Test</p></fn><fn id="Fs3tbl1c"><p><sup>c</sup> Chi- Square Test</p></fn></table-wrap-foot></table-wrap><p>The mean HBs Ab level after 4 doses of the 40 &#x003bc;g vaccine (182.2 &#x000b1; 286.7) was higher than that after 3 doses of the 20 &#x003bc;g vaccine (107.6 &#x000b1; 192.1), but the difference was not significant (P = 0.3). After 4 doses of the 40 &#x003bc;g vaccine, the cumulative seroconversion rate (HBs Ab &#x02265; 10 mIU/ml) was not significantly different (21/26, 80.8%) than that after 3 doses of 20 &#x003bc;g (23/25, 92%) P = 0.41). The mean HBs Ab level after 4 doses of 40 &#x003bc;g (182.2 &#x000b1; 286.7) was significantly higher than that attained after 3 doses of the 40 &#x003bc;g vaccine (96.9 &#x000b1; 192.1) (P = 0.004). In addition, after 4 doses of 40 &#x003bc;g (21/26, 80.8%), the seroconversion rate was higher than that after 3 doses of 40 &#x003bc;g (20/26, 77%). There was no correlation between age and serum HBs Ab level in the 3-dose group; however, there was a negative correlation in the 4-dose group (r = -0.58, P = 0.002).</p><sec id="s3sub6"><title>3.1. Multivariable Analysis</title><p>In the logistic regression analysis (<xref ref-type="table" rid="s3sub6tbl2">Table 2</xref>), there was no difference between the group receiving 3 doses of 20 &#x003bc;g and those receiving 4 doses of 40 &#x003bc;g of HBV vaccine in terms of predicting the proportion with seroconversion, adjusting for age, ferritin, FBS, HDL, Alb, weight, and HCV Ab.</p><table-wrap id="s3sub6tbl2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Logistic Regression Analysis to Determine Predictors of Antibody Response (HBs Ab &#x02265; 10 mIU/ml) After 3 Doses of 20 &#x000b5;g and 4 Doses of 40 &#x000b5;g, HBV Vaccination</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><bold><italic>P </italic>value</bold></td><td rowspan="1" colspan="1"><bold>OR <xref ref-type="table-fn" rid="Fs3sub6tbl2a">a</xref></bold></td><td colspan="2" align="center" rowspan="1"><bold>95.0% CI For OR</bold></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><bold>Lower</bold></td><td rowspan="1" colspan="1"><bold>Upper</bold></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">2 vaccination schedule</td><td rowspan="1" colspan="1">0.17</td><td rowspan="1" colspan="1">0.16</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">2.18</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">0.53</td><td rowspan="1" colspan="1">1.05</td><td rowspan="1" colspan="1">0.90</td><td rowspan="1" colspan="1">1.21</td></tr><tr><td rowspan="1" colspan="1">Ferritin</td><td rowspan="1" colspan="1">0.18</td><td rowspan="1" colspan="1">1.03</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">1.07</td></tr><tr><td rowspan="1" colspan="1">FBS <xref ref-type="table-fn" rid="Fs3sub6tbl2a">a</xref>, <xref ref-type="table-fn" rid="Fs3sub6tbl2b">b</xref></td><td rowspan="1" colspan="1">0.52</td><td rowspan="1" colspan="1">2.90</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">77.18</td></tr><tr><td rowspan="1" colspan="1">HDL<xref ref-type="table-fn" rid="Fs3sub6tbl2a">a</xref>, <xref ref-type="table-fn" rid="Fs3sub6tbl2c">c</xref></td><td rowspan="1" colspan="1">0.49</td><td rowspan="1" colspan="1">0.33</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">8.14</td></tr><tr><td rowspan="1" colspan="1">Albumin<xref ref-type="table-fn" rid="Fs3sub6tbl2d">d</xref></td><td rowspan="1" colspan="1">0.28</td><td rowspan="1" colspan="1">8.55</td><td rowspan="1" colspan="1">0.17</td><td rowspan="1" colspan="1">433.64</td></tr><tr><td rowspan="1" colspan="1">Weight</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">1.22</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">1.51</td></tr><tr><td rowspan="1" colspan="1">HCV Ab(+/-)</td><td rowspan="1" colspan="1">0.46</td><td rowspan="1" colspan="1">0.32</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">6.76</td></tr><tr><td rowspan="1" colspan="1">Constant</td><td rowspan="1" colspan="1">0.17</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="Fs3sub6tbl2a"><p><sup>a</sup> Abbreviations: FBS, Fasting Blood Sugar; HDL, High-density lipoprotein</p></fn><fn id="Fs3sub6tbl2b"><p><sup>b</sup> FBS &#x02264; 100 is based</p></fn><fn id="Fs3sub6tbl2c"><p><sup>c</sup> HDL &#x02264; 40 is based</p></fn><fn id="Fs3sub6tbl2d"><p><sup>d</sup> Albumin &#x02264; 4 is based</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>4. Discussion</title><p>Patients with renal insufficiency have a suboptimal response to HBV vaccination, and frequent boosters are needed to maintain protection [<xref ref-type="bibr" rid="R23">23</xref>][<xref ref-type="bibr" rid="R24">24</xref>]. We compared 2 HBV vaccination schedules, namely 20 &#x003bc;g at 0, 1, and 6 months and 40 &#x003bc;g at 0, 1, 2, and 6 months. There was no significant difference in the seroconversion rate between the 40 &#x003bc;g 4-dose vaccination group (21/26, 80.8%) and the 20 &#x003bc;g 3-dose group (23/25, 92%). These findings support the McNulty et al. study results [<xref ref-type="bibr" rid="R22">22</xref>]. In that study, 3 doses of 40 &#x003bc;g (67%) attained equivalent seroconversion to 3 doses of 20 &#x003bc;g.(57%) [<xref ref-type="bibr" rid="R22">22</xref>]. In our study, the mean HBs Ab level after 4 doses of 40 &#x003bc;g (182.2 &#x000b1; 286.7) was significantly higher than that after 3 doses of 40 &#x003bc;g (96.9 &#x000b1; 192.1) (P = 0.004). In addition, seroconversion was greater after 4 doses of 40 &#x003bc;g (21/26, 80.8%) compared with after 3 doses of 40 &#x003bc;g (20/26, 77%). As reported in some other studies [<xref ref-type="bibr" rid="R25">25</xref>][<xref ref-type="bibr" rid="R26">26</xref>], dialysis patients who did not seroconvert after the 3-dose course often did seroconvert after the fourth dose. Agarwal et al. [<xref ref-type="bibr" rid="R26">26</xref>] compared 2 HBV 40 &#x003bc;g vaccination schedules among patients with mild, moderate, and severe chronic renal failure (CRF): 0,1, and 2 months (3-dose group) vs. 0,1,2, and 6 months (4-dose group). In the 3-dose group, the seroconversion rate among those with mild, moderate, and severe CRF was 87.5%, 66.6%, and 35.7%, respectively, and in 4-dose group it was 100%, 77%, and 36.36%. They concluded that patients with CRF should be vaccinated at the very early stage of the disease using 40 &#x003bc;g of vaccine, and that 4 doses is better than 3 doses [<xref ref-type="bibr" rid="R26">26</xref>].</p><p>McNulty et al. showed that the median age of the seroconverter group was about 7.5 years lower than that of the non-seroconverter group; however, this difference was not significant [<xref ref-type="bibr" rid="R22">22</xref>]. Fabrizi et al. [<xref ref-type="bibr" rid="R27">27</xref>] conducted a meta-analysis of 17 clinical trials involving end-stage renal disease patients, and found an association between older age and impaired response to the HBV vaccine. In another study in Iran, higher age (&#x0003e; 60 years) was negatively correlated with seroconversion (odds ratio = 0.22; P = 0.004). [<xref ref-type="bibr" rid="R28">28</xref>] In our study, there was no correlation between age and serum HBs Ab level in the 3-dose group; however, there was a negative correlation in the 4-dose group (r= -0.58, P = 0.002). Similar to other reports [<xref ref-type="bibr" rid="R22">22</xref>][<xref ref-type="bibr" rid="R29">29</xref>], in this study, there was no noticeable association between GFR and seroconversion rate. The sample size was too small to notice a significant difference. A study investigating the effect of renal function on seroconversion rates suggested that CKD patients with higher GFR levels were more likely to respond to vaccination [<xref ref-type="bibr" rid="R30">30</xref>]. The overall vaccine response rate was 86.27%. This was similar to DaRoza et al.&#x02019;s study [<xref ref-type="bibr" rid="R30">30</xref>]. The seroconversion rate in the Hashemi et al. study was 78%, (lower than the results of our study) [<xref ref-type="bibr" rid="R28">28</xref>]. Edey et al. [<xref ref-type="bibr" rid="R31">31</xref>] in a review article explained that the 3-dose schedule of HBV vaccine in immunocompetent individuals may lead to a 90&#x02013;95% seroprotection rate; however, in patients with renal failure, the rates were lower. They suggested that dialysis patients should receive higher vaccine doses such as 40 &#x000b5;g at 0, 1, and 6 months, or 40 &#x000b5;g at 0, 1, 2, and 6 months to improve immune response. In this review, the best reported response rates to these schedules were &#x0003c; 85% [<xref ref-type="bibr" rid="R31">31</xref>]. Joukar et al. [<xref ref-type="bibr" rid="R32">32</xref>], in a study of hemodialysis patients in Guilan, north of Iran, concluded that despite the low rate of HBV infection in that region, HBV vaccination of end-stage renal disease patients before chronic hemodialysis can prevent HBV infection [<xref ref-type="bibr" rid="R32">32</xref>].</p><p>In our study, seroconversion (HBs Ab &#x02265; 10 mIU/ml) in the 40&#x003bc;g 4 dose group was 80.8%, and in 20 &#x003bc;g 3 dose group was 92%, (P = 0.41).</p><p>The mean antibody titers after three doses of 20 &#x003bc;g vaccine (107.6 &#x000b1; 192.1), was lower than four doses of 40 &#x003bc;g (182.2 &#x000b1; 286.7), but was not significant.</p><p>We hypothesized that four doses of 40&#x003bc;g may be better than three doses of 20&#x003bc;g, but we did not find any difference between two methods. These results may be related to small sample size, large standard deviation of HBs Ab levels, and lack of statistical power.</p><p>Limitations of the study: The sample size available for this time of study regarding to inclusion and exclusion criteria and time period did not reach to calculated sample size.</p></sec><sec id="s5"><title>5. Conclusion</title><p>We found that the 4-dose 40 &#x003bc;g HBV vaccine did not lead to significantly greater seroconversion than 3 doses of 20 &#x003bc;g. Thus, it is perhaps not necessary to introduce a 4-dose 40 &#x003bc;g HBV vaccination schedule to replace the 3-dose 20 &#x003bc;g schedule for predialysis vaccination of patients with stage 3 and 4 CKD. However, further studies with a larger sample size are required.</p></sec></body><back><ack><p>None declared.</p></ack><fn-group><fn fn-type="other"><p><bold>Implication for health policy/practice/research/medical education: </bold>This article presents Hepatitis B Vaccination in Patients with chronic renal disease.</p></fn><fn fn-type="other"><p><bold>Please cite this paper as: </bold>Ahmadi F, Ramezani M, Razeghi E, Ranjbarnovin N, Khazaeipour Z. A randomized Controlled Trial of Two Schedules of Hepatitis B Vaccination in Predialysed Chronic Renal Failure Patients. Hepat Mon. 2012;12(5): 344-8. DOI: 10.5812/hepatmon.6438</p></fn><fn fn-type="other"><p><bold>Authors&#x02019; Contribution: </bold>Authors has been worked equally on this study</p></fn><fn fn-type="financial-disclosure"><p><bold>Financial Disclosure: </bold>None declared.</p></fn><fn fn-type="other"><p><bold>Funding/Support: </bold>All authors disclose that they had no actual or potential conflict of interest including any financial, personal, or other relationships with relevant individuals or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work.</p></fn><fn fn-type="other"><p><bold>NCT registration identifier: </bold>NCT01468051</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>KN</given-names></name></person-group><article-title>Chronic viral hepatitis in hemodialysis patients</article-title><source>Hemodial Int</source><year>2005</year><volume>9</volume><issue>2</issue><fpage>169</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/j.1492-7535.2005.01129.x</pub-id><pub-id pub-id-type="pmid">16191066</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recommendation of the Immunization Practices Advisory Committee (ACIP).</surname><given-names/></name></person-group><article-title>Inactivated hepatitis B virus vaccine.</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>1982</year><volume>31</volume><issue>24</issue><fpage>317</fpage><lpage>22, 27-8</lpage><pub-id pub-id-type="pmid">6811846</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dijk</surname><given-names>PC</given-names></name><name><surname>Jager</surname><given-names>KJ</given-names></name><name><surname>de Charro</surname><given-names>F</given-names></name><name><surname>Collart</surname><given-names>F</given-names></name><name><surname>Cornet</surname><given-names>R</given-names></name><name><surname>Dekker</surname><given-names>FW</given-names></name><etal/></person-group><article-title>Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries.</article-title><source>Nephrol Dial Transplant</source><year>2001</year><volume>16</volume><issue>6</issue><fpage>1120</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/ndt/16.6.1120</pub-id><pub-id pub-id-type="pmid">11390709</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Fleming</surname><given-names>SJ</given-names></name></person-group><article-title>The use of vaccines in renal failure.</article-title><source>Clin Pharmacokinet</source><year>1992</year><volume>22</volume><issue>6</issue><fpage>434</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.2165/00003088-199222060-00003</pub-id><pub-id pub-id-type="pmid">1587056</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finelli</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>JT</given-names></name><name><surname>Tokars</surname><given-names>JI</given-names></name><name><surname>Alter</surname><given-names>MJ</given-names></name><name><surname>Arduino</surname><given-names>MJ</given-names></name></person-group><article-title>National surveillance of dialysis-associated diseases in the United States, 2002.</article-title><source>Semin Dial</source><year>2005</year><volume>18</volume><issue>1</issue><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1525-139X.2005.18108.x</pub-id><pub-id pub-id-type="pmid">15663766</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><article-title>Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials.</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2008</year><volume>57</volume><issue>32</issue><fpage>875</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18701878</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peces</surname><given-names>R</given-names></name><name><surname>de la Torre</surname><given-names>M</given-names></name><name><surname>Alcazar</surname><given-names>R</given-names></name><name><surname>Urra</surname><given-names>JM</given-names></name></person-group><article-title>Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients.</article-title><source>Am J Kidney Dis</source><year>1997</year><volume>29</volume><issue>2</issue><fpage>239</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(97)90036-6</pub-id><pub-id pub-id-type="pmid">9016896</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pesanti</surname><given-names>EL</given-names></name></person-group><article-title>Immunologic defects and vaccination in patients with chronic renal failure.</article-title><source>Infect Dis Clin North Am</source><year>2001</year><volume>15</volume><issue>3</issue><fpage>813</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/S0891-5520(05)70174-4</pub-id><pub-id pub-id-type="pmid">11570143</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Docci</surname><given-names>D</given-names></name><name><surname>Cipolloni</surname><given-names>PA</given-names></name><name><surname>Mengozzi</surname><given-names>S</given-names></name><name><surname>Baldrati</surname><given-names>L</given-names></name><name><surname>Capponcini</surname><given-names>C</given-names></name><name><surname>Feletti</surname><given-names>C</given-names></name></person-group><article-title>Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up.</article-title><source>Nephron</source><year>1992</year><volume>61</volume><issue>3</issue><fpage>352</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1159/000186939</pub-id><pub-id pub-id-type="pmid">1386909</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitwalli</surname><given-names>A</given-names></name></person-group><article-title>Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling.</article-title><source>Nephron</source><year>1996</year><volume>73</volume><issue>3</issue><fpage>417</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1159/000189103</pub-id><pub-id pub-id-type="pmid">8832600</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabrizi</surname><given-names>F</given-names></name><name><surname>Dixit</surname><given-names>V</given-names></name><name><surname>Magnini</surname><given-names>M</given-names></name><name><surname>Elli</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name></person-group><article-title>Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease.</article-title><source>Aliment Pharmacol Ther</source><year>2006</year><volume>24</volume><issue>3</issue><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.03002.x</pub-id><pub-id pub-id-type="pmid">16886915</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodersen</surname><given-names>HP</given-names></name><name><surname>Holtkamp</surname><given-names>W</given-names></name><name><surname>Larbig</surname><given-names>D</given-names></name><name><surname>Beckers</surname><given-names>B</given-names></name><name><surname>Thiery</surname><given-names>J</given-names></name><name><surname>Lautenschlager</surname><given-names>J</given-names></name><etal/></person-group><article-title>Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: a multicentre study.</article-title><source>Nephrol Dial Transplant</source><year>1995</year><volume>10</volume><issue>9</issue><fpage>1780</fpage><pub-id pub-id-type="pmid">8559509</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argani</surname><given-names>H</given-names></name><name><surname>Akhtarishojaie</surname><given-names>E</given-names></name></person-group><article-title>Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients.</article-title><source>J Immune Based Ther Vaccines</source><year>2006</year><volume>4</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1476-8518-4-3</pub-id><pub-id pub-id-type="pmid">16734912</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quiroga</surname><given-names>JA</given-names></name><name><surname>Castillo</surname><given-names>I</given-names></name><name><surname>Porres</surname><given-names>JC</given-names></name><name><surname>Casado</surname><given-names>S</given-names></name><name><surname>Saez</surname><given-names>F</given-names></name><name><surname>Gracia Martinez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients.</article-title><source>Hepatology</source><year>1990</year><volume>12</volume><issue>4 Pt 1</issue><fpage>661</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1002/hep.1840120407</pub-id><pub-id pub-id-type="pmid">2145212</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungers</surname><given-names>P</given-names></name><name><surname>Devillier</surname><given-names>P</given-names></name><name><surname>Salomon</surname><given-names>H</given-names></name><name><surname>Cerisier</surname><given-names>JE</given-names></name><name><surname>Courouce</surname><given-names>AM</given-names></name></person-group><article-title>Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine.</article-title><source>Lancet</source><year>1994</year><volume>344</volume><issue>8926</issue><fpage>856</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)92829-0</pub-id><pub-id pub-id-type="pmid">7916403</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verkade</surname><given-names>MA</given-names></name><name><surname>van de Wetering</surname><given-names>J</given-names></name><name><surname>Klepper</surname><given-names>M</given-names></name><name><surname>Vaessen</surname><given-names>LM</given-names></name><name><surname>Weimar</surname><given-names>W</given-names></name><name><surname>Betjes</surname><given-names>MG</given-names></name></person-group><article-title>Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients.</article-title><source>Kidney Int</source><year>2004</year><volume>66</volume><issue>2</issue><fpage>614</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00781.x</pub-id><pub-id pub-id-type="pmid">15253714</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangel</surname><given-names>MC</given-names></name><name><surname>Coronado</surname><given-names>VG</given-names></name><name><surname>Euler</surname><given-names>GL</given-names></name><name><surname>Strikas</surname><given-names>RA</given-names></name></person-group><article-title>Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics.</article-title><source>Semin Dial</source><year>2000</year><volume>13</volume><issue>2</issue><fpage>101</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1046/j.1525-139x.2000.00029.x</pub-id><pub-id pub-id-type="pmid">10795113</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>KM</given-names></name><name><surname>Law</surname><given-names>MC</given-names></name><name><surname>Leung</surname><given-names>CB</given-names></name><name><surname>Szeto</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>PK</given-names></name></person-group><article-title>Antibody response to hepatitis B vaccine in end-stage renal disease patients.</article-title><source>Nephron Clin Pract</source><year>2006</year><volume>103</volume><issue>3</issue><fpage>c89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1159/000092016</pub-id><pub-id pub-id-type="pmid">16534237</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dukes</surname><given-names>CS</given-names></name><name><surname>Street</surname><given-names>AC</given-names></name><name><surname>Starling</surname><given-names>JF</given-names></name><name><surname>Hamilton</surname><given-names>JD</given-names></name></person-group><article-title>Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis.</article-title><source>Vaccine</source><year>1993</year><volume>11</volume><issue>12</issue><fpage>1229</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(93)90047-2</pub-id><pub-id pub-id-type="pmid">8256504</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seaworth</surname><given-names>B</given-names></name><name><surname>Drucker</surname><given-names>J</given-names></name><name><surname>Starling</surname><given-names>J</given-names></name><name><surname>Drucker</surname><given-names>R</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Hamilton</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis B vaccines in patients with chronic renal failure before dialysis.</article-title><source>J Infect Dis</source><year>1988</year><volume>157</volume><issue>2</issue><fpage>332</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/infdis/157.2.332</pub-id><pub-id pub-id-type="pmid">2961818</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bel&#x02019;eed</surname><given-names>K</given-names></name><name><surname>Wright</surname><given-names>M</given-names></name><name><surname>Eadington</surname><given-names>D</given-names></name><name><surname>Farr</surname><given-names>M</given-names></name><name><surname>Sellars</surname><given-names>L</given-names></name></person-group><article-title>Vaccination against hepatitis B infection in patients with end stage renal disease.</article-title><source>Postgrad Med J</source><year>2002</year><volume>78</volume><issue>923</issue><fpage>538</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1136/pmj.78.923.538</pub-id><pub-id pub-id-type="pmid">12357014</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNulty</surname><given-names>CA</given-names></name><name><surname>Bowen</surname><given-names>JK</given-names></name><name><surname>Williams</surname><given-names>AJ</given-names></name></person-group><article-title>Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules.</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><issue>32</issue><fpage>4142</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.03.020</pub-id><pub-id pub-id-type="pmid">15913854</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waite</surname><given-names>NM</given-names></name><name><surname>Thomson</surname><given-names>LG</given-names></name><name><surname>Goldstein</surname><given-names>MB</given-names></name></person-group><article-title>Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine.</article-title><source>J Am Soc Nephrol</source><year>1995</year><volume>5</volume><issue>11</issue><fpage>1930</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7620090</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>PC</given-names></name><name><surname>Schrander-van der Meer</surname><given-names>AM</given-names></name><name><surname>van Dorp</surname><given-names>WT</given-names></name><name><surname>van Leer</surname><given-names>E</given-names></name></person-group><article-title>Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients.</article-title><source>Nephrol Dial Transplant</source><year>1996</year><volume>11</volume><issue>1</issue><fpage>191</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.ndt.a027041</pub-id><pub-id pub-id-type="pmid">8649634</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosman</surname><given-names>AS</given-names></name><name><surname>Lieber</surname><given-names>CS</given-names></name></person-group><article-title>Improving the response to hepatitis B vaccine.</article-title><source>Infect Med</source><year>1999</year><volume>16</volume><fpage>205</fpage><lpage>1810</lpage></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Irshad</surname><given-names>M</given-names></name><name><surname>Dash</surname><given-names>SC</given-names></name></person-group><article-title>Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure.</article-title><source>J Assoc Physicians India</source><year>1999</year><volume>47</volume><issue>2</issue><fpage>183</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10999085</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabrizi</surname><given-names>F</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Dixit</surname><given-names>V</given-names></name><name><surname>Bunnapradist</surname><given-names>S</given-names></name><name><surname>Dulai</surname><given-names>G</given-names></name></person-group><article-title>Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease.</article-title><source>Aliment Pharmacol Ther</source><year>2004</year><volume>20</volume><issue>10</issue><fpage>1053</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2004.02264.x</pub-id><pub-id pub-id-type="pmid">15569107</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashemi</surname><given-names>B</given-names></name><name><surname>Mahdavi-Mazdeh</surname><given-names>M</given-names></name><name><surname>Abbasi</surname><given-names>M</given-names></name><name><surname>Hosseini-Moghaddam</surname><given-names>SM</given-names></name><name><surname>Zinat</surname><given-names>NH</given-names></name><name><surname>Ahmadi</surname><given-names>F</given-names></name></person-group><article-title>Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better?</article-title><source>Hepat Mon</source><year>2011</year><volume>11</volume><issue>10</issue><fpage>816</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.5812/kowsar.1735143X.751</pub-id><pub-id pub-id-type="pmid">22224080</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>GM</given-names></name><name><surname>Ochana</surname><given-names>N</given-names></name><name><surname>Fenyves</surname><given-names>D</given-names></name><name><surname>Neumann</surname><given-names>L</given-names></name><name><surname>Chazan</surname><given-names>R</given-names></name><name><surname>Niv</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients.</article-title><source>J Hepatol</source><year>1994</year><volume>21</volume><issue>3</issue><fpage>450</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(05)80327-7</pub-id><pub-id pub-id-type="pmid">7836717</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DaRoza</surname><given-names>G</given-names></name><name><surname>Loewen</surname><given-names>A</given-names></name><name><surname>Djurdjev</surname><given-names>O</given-names></name><name><surname>Love</surname><given-names>J</given-names></name><name><surname>Kempston</surname><given-names>C</given-names></name><name><surname>Burnett</surname><given-names>S</given-names></name><etal/></person-group><article-title>Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better.</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>42</volume><issue>6</issue><fpage>1184</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2003.08.019</pub-id><pub-id pub-id-type="pmid">14655190</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edey</surname><given-names>M</given-names></name><name><surname>Barraclough</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name></person-group><article-title>Review article: Hepatitis B and dialysis.</article-title><source>Nephrology (Carlton).</source><year>2010</year><volume>15</volume><issue>2</issue><fpage>137</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1797.2009.01268.x</pub-id><pub-id pub-id-type="pmid">20470270</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joukar</surname><given-names>F</given-names></name><name><surname>Besharati</surname><given-names>S</given-names></name><name><surname>Mirpour</surname><given-names>H</given-names></name><name><surname>Mansour-Ghanaei</surname><given-names>F</given-names></name></person-group><article-title>Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients.</article-title><source>Hepat Mon</source><year>2011</year><volume>11</volume><issue>3</issue><fpage>178</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">22087139</pub-id></element-citation></ref></ref-list></back></article>